F. R. Hirsch

546 total citations
26 papers, 449 citations indexed

About

F. R. Hirsch is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, F. R. Hirsch has authored 26 papers receiving a total of 449 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Pulmonary and Respiratory Medicine, 11 papers in Oncology and 5 papers in Molecular Biology. Recurrent topics in F. R. Hirsch's work include Lung Cancer Treatments and Mutations (15 papers), Lung Cancer Diagnosis and Treatment (10 papers) and Colorectal Cancer Treatments and Studies (5 papers). F. R. Hirsch is often cited by papers focused on Lung Cancer Treatments and Mutations (15 papers), Lung Cancer Diagnosis and Treatment (10 papers) and Colorectal Cancer Treatments and Studies (5 papers). F. R. Hirsch collaborates with scholars based in United States, Denmark and Poland. F. R. Hirsch's co-authors include Wilbur A. Franklin, Roy M. Bremnes, Harry A. Drabkin, Anna E. Barón, Edward Gabrielson, Robert Veve, Lynne Bemis, Robert M. Gemmill, W. Franklin and P. A. Bunn and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Respiratory Journal.

In The Last Decade

F. R. Hirsch

25 papers receiving 434 citations

Peers

Countries citing papers authored by F. R. Hirsch

Since Specialization

Citations

This map shows the geographic impact of F. R. Hirsch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F. R. Hirsch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F. R. Hirsch more than expected).

Fields of papers citing papers by F. R. Hirsch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F. R. Hirsch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F. R. Hirsch. The network helps show where F. R. Hirsch may publish in the future.

Co-authorship network of co-authors of F. R. Hirsch

This figure shows the co-authorship network connecting the top 25 collaborators of F. R. Hirsch. A scholar is included among the top collaborators of F. R. Hirsch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F. R. Hirsch. F. R. Hirsch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	An AI Approach to Differentiating Lung Squamous Cell Carcinoma From Metastases of Other Origins 2026 ·JAMA Network Open ·M. Evans, Jennifer R. Ribeiro, Todd Maney, (unknown), (unknown), Anthony N. Karnezis, Casey Bales, (unknown), (unknown), (unknown), Matthew J. Oberley, (unknown), (unknown), (unknown), (unknown), F. R. Hirsch, (unknown)	0
2	LBA75 Defining COVID-19 outcomes in thoracic cancer patients: TERAVOLT (Thoracic cancERs international coVid 19 cOLlaboraTion) 2020 ·Annals of Oncology ·(unknown), Valter Torri, Jennifer G. Whisenant, F. R. Hirsch, Jacobo Rogado, Javier de Castro, Balázs Halmos, Giovanni Luca Ceresoli, (unknown), Marcello Tiseo, Enriqueta Felip, (unknown), I. Monnet, Ümit Tapan, Heather A. Wakelee, (unknown), Marina Chiara Garassino, Solange Peters, Leora Horn, Matthew D. Hellmann	7
3	Meta-analysis of the predictive and prognostic value of erlotinib-related biomarkers in phase III, placebo-controlled trials in non-small cell lung cancer (NSCLC): Recommendations of the BioLOGUE advisors. 2011 ·Journal of Clinical Oncology ·(unknown), Jürgen Wolf, Frances A. Shepherd, Federico Cappuzzo, P. A. Bunn, Roy S. Herbst, F. R. Hirsch, Keith M. Kerr, Tetsuya Mitsudomi, Ming‐Sound Tsao, (unknown), Frank C. Richardson, Barbara Klughammer, Bret Wacker, David Sternberg, Angela M. Davies	8
4	Predictive value of thymidylate synthase and folylpoly-glutamate synthetase for clinical benefit from pemetrexed in malignant pleural mesothelioma. 2011 ·Journal of Clinical Oncology ·Daniel C. Christoph, Céline Mascaux, Murry W. Wynes, Bernadette Reyna Asuncion, Jeremias Wohlschlaeger, Dirk Theegarten, Thomas Gauler, (unknown), Wilfried Eberhardt, F. R. Hirsch	1
5	Thymidylate synthase (TS) gene copy number in NSCLC. 2010 ·Journal of Clinical Oncology ·Murry W. Wynes, Rafał Dziadziuszko, Shambhavi Singh, James Ranger‐Moore, Barbara Szostakiewicz, (unknown), Jacek Jassem, F. R. Hirsch	2
6	Synergistic effect of SNDX-275 with lapatinib or erlotinib in breast, lung, or head and neck cancer cell lines expressing HER- 2 2009 ·Journal of Clinical Oncology ·Samir E. Witta, (unknown), Kimihide Yoshida, (unknown), Barbara Frederick, Marileila Varella‐Garcia, P. A. Bunn, F. R. Hirsch	1
7	Analysis of IGF1R gene copy number by silver in situ hybridization (SISH) in non-small cell lung cancer (NSCLC) 2009 ·Journal of Clinical Oncology ·Murry W. Wynes, Sharat Singh, Rafał Dziadziuszko, (unknown), K Jaśkiewicz, Jacek Jassem, (unknown), F. R. Hirsch	3
8	RTOG 0324: A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients with stage IIIA/B non-small cell lung cancer (NSCLC)—Association between EGFR gene copy number and patients’ outcome 2008 ·Journal of Clinical Oncology ·Christine Olsen, Rebecca Paulus, R. Komaki, M. Varella-Garcia, Rafał Dziadziuszko, Walter J. Curran, Francisco Robert, H. Choy, G. R. Blumenschein, F. R. Hirsch	5
9	Long-term survival with gefitinib (ZD 1839) therapy for advanced bronchioloalveolar lung cancer (BAC): Southwest Oncology Group (SWOG) study S0126 2008 ·Journal of Clinical Oncology ·Howard West, Kari Chansky, Wilbur A. Franklin, F. R. Hirsch, John J. Crowley, Denise Lau, David R. Gandara	3
10	FISHing for lung cancer: Promising findings using multi-targeted interphase fluorescence in situ hybridization (FISH) for lung cancer detection in sputum 2007 ·Journal of Clinical Oncology ·Wilbur A. Franklin, T. Byers, Holly J. Wolf, (unknown), F. R. Hirsch, Y E Miller, Robert L. Keith, Timothy C. Kennedy, Steven A. Belinsky, M. Varella-Garcia	1
11	Erlotinib as initial therapy in patients with advanced non-small cell lung cancer (NSCLC) and a performance status (PS) of 2: A SWOG phase II trial (S0341) 2007 ·Journal of Clinical Oncology ·Paul J. Hesketh, Kari Chansky, (unknown), (unknown), Primo N. Lara, W. Franklin, F. R. Hirsch, John Crowley, David R. Gandara	9
12	Epidermal growth factor receptor gene copy number and protein level are not associated with outcome of non-small-cell lung cancer patients treated with chemotherapy 2006 ·Annals of Oncology ·Rafał Dziadziuszko, Bente Holm, (unknown), Kell Østerlind, (unknown), W. Franklin, P. A. Bunn, Marileila Varella‐Garcia, F. R. Hirsch	37
13	Predicting clinical benefit from EGFR TKIs: Not all EGFR mutations are equal 2006 ·Journal of Clinical Oncology ·F. R. Hirsch, Wilbur A. Franklin, J. McCoy, Federico Cappuzzo, Marileila Varella‐Garcia, Samir E. Witta, Paul H. Gumerlock, Howard West, David R. Gandara, Paul A. Bunn	19
14	Prognostic significance of EGFR FISH and IHC in non small-cell lung cancer patients treated with chemotherapy alone 2006 ·Journal of Clinical Oncology ·Rafał Dziadziuszko, Bente Holm, (unknown), Kell Østerlind, Wilbur A. Franklin, M. Varella-Garcia, P. A. Bunn, F. R. Hirsch	1
15	Studies of pemetrexed and gemcitabine, alone and in combinations, in human lung cancer models 2006 ·Journal of Clinical Oncology ·Dan Chan, (unknown), (unknown), B. Helfrich, F. R. Hirsch, Di Ma, P. A. Bunn	4
16	Prediction of clinical outcome in non-small cell lung cancer (NSCLC) patients treated with gefitinib using Matrix-Assisted Laser Desorption/Ionization-Time of Flight Mass Spectrometry (MALDI-TOF MS) of serum 2006 ·Journal of Clinical Oncology ·Brad Solomon, Vanesa Gregorc, (unknown), Kazuo Kasahara, Mizuho Nishio, Heinrich Röder, F. R. Hirsch, Mark W. Duncan, P. A. Bunn, D. Carbone	3
17	Defining gefitinib sensitivity/resistance in non-small cell lung cancer (NSCLC) cell lines by affymetrix gene arrays 2004 ·Journal of Clinical Oncology ·F. R. Hirsch, Wilbur A. Franklin, Samir E. Witta, B. Helfrich, Razvan Lapadat, Christopher D. Coldren, Michio Sugita, P. A. Bunn	3
18	A histopathologic evaluation of premalignant and early malignant bronchial lesions: An interactive program based on internet digital images to improve WHO criteria for early diagnosis of lung cancer and for monitoring chemoprevention studies—A SPORE collaborative project 2000 ·Lung Cancer ·F. R. Hirsch, Adi F. Gazdar, E Gabrielson, (unknown), W. Franklin	9
19	A review of the 5th World Conference on Lung Cancer held by the International Association for the Study of Lung Cancer 1989 ·European Respiratory Journal ·Paul E.G. Kristjansen, F. R. Hirsch	4
20	Prophylactic irradiation in bronchogenic small cell anaplastic carcinoma 1980 ·OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) ·Heine H. Hansen, P Dombernowsky, F. R. Hirsch, M Hansen, J Rygård	33

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact